<DOC>
	<DOCNO>NCT00799877</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety Humira® Adult Patients Chronic Plaque Psoriasis ( Ps ) .</brief_summary>
	<brief_title>Chronic Plaque Psoriasis ( Ps ) Registry</brief_title>
	<detailed_description>ESPRIT 10 year registry patient take HUMIRA® Psoriasis . Patients volunteer participate ask provide information medical history experience HUMIRA® . No registry specific test perform . Patients ask provide data experience HUMIRA® approximately every 6 month , determine study doctor . No drug provide result participation registry . All treatment decision independent participation registry .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . An adult patient ( 18 year age old ) chronic plaque psoriasis prescribe HUMIRA® therapy accord local product label meet one follow criterion : New initiate ( within 4 week registry entry ) HUMIRA® therapy ; Initiated HUMIRA® therapy past : Has receive continuous ( 70 consecutive day drug ) HUMIRA® therapy physician provide source documentation SAEs , AEs , Special Interest , dose information since initiation therapy . OR Is enter participation AbbVie HUMIRA ( adalimumab ) sponsor study receive continuous ( 70 consecutive day drug ) HUMIRA® therapy completion AbbVie sponsor study physician provide source documentation SAEs , AEs Special Interest , dose information since initiation commercial HUMIRA® ( define prescribed/non study drug ) . 2 . Patient willing consent data collect provided AbbVie ; 3 . Patient capable willing give write informed consent comply requirement registry . 1 . Patient enrol he/she treat accordance local product label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Severe Chronic Plaque Psoriasis</keyword>
	<keyword>Registry</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Moderate Psoriasis</keyword>
</DOC>